Caspase 3

Structure

Caspase-3, in particular, (also known as CPP32/Yama/apopain) is formed from a 32 kDa zymogen that is cleaved into 17 kDa and 12 kDa subunits. When the procaspase is cleaved at a particular residue, the active heterotetramer can then be formed by hydrophobic interactions, causing four anti-parallel beta-sheets from p17 and two from p12 to come together to make a heterodimer, which in turn interacts with another heterodimer to form the full 12-stranded beta-sheet structure surrounded by alpha-helices that is unique to caspases. When the heterodimers align head-to-tail with each other, an active site is positioned at each end of the molecule formed by residues from both participating subunits, though the necessary Cys-163 and His-121 residues are found on the p17 (larger) subunit.

Function

Caspase-3 is a crucial executioner protease in the apoptotic pathway, responsible for orchestrating the dismantling of cellular components during programmed cell death. Synthesized as an inactive zymogen, caspase-3 is activated by upstream initiator caspases-such as caspase-8 and caspase-9 through proteolytic cleavage, which exposes its active site and enables it to cleave a broad range of cellular substrates, including structural proteins, cell cycle regulators, and DNA repair enzymes. This proteolytic activity leads to hallmark features of apoptosis, such as chromatin condensation, DNA fragmentation, and the formation of apoptotic bodies, facilitating the orderly removal of dying cells. Caspase-3's function is tightly regulated by post-translational modifications and interactions with other cellular proteins, ensuring that apoptosis proceeds only under appropriate physiological conditions. Its essential role is underscored by its requirement for normal development and tissue homeostasis, and dysregulation of caspase-3 activity has been implicated in various diseases, including neurodegenerative disorders and cancer[7].

Caspase-3 has been found to be necessary for normal brain development as well as its typical role in apoptosis, where it is responsible for chromatin condensation and DNA fragmentation. Elevated levels of a fragment of Caspase-3, p17, in the bloodstream is a sign of a recent myocardial infarction. It is now being shown that caspase-3 may play a role in embryonic and hematopoietic stem cell differentiation.

Enzymatic activity

Substrate specificity

Under normal circumstances, caspases recognize tetra-peptide sequences on their substrates and hydrolyze peptide bonds after aspartic acid residues. Caspase 3 and caspase 7 share similar substrate specificity by recognizing tetra-peptide motif Asp-x-x-Asp. The C-terminal Asp is absolutely required while variations at other three positions can be tolerated. Caspase substrate specificity has been widely used in caspase based inhibitor and drug design.

Mechanism of catalysis

The catalytic site of caspase-3 involves the thiol group of Cys-163 and the imidazole ring of His-121. His-121 stabilizes the carbonyl group of the key aspartate residue, while Cys-163 attacks to ultimately cleave the peptide bond. Cys-163 and Gly-238 also function to stabilize the tetrahedral transition state of the substrate-enzyme complex through hydrogen bonding. In vitro, caspase-3 has been found to prefer the peptide sequence DEVDG (Asp-Glu-Val-Asp-Gly) with cleavage occurring on the carboxy side of the second aspartic acid residue (between D and G). Caspase-3 is active over a broad pH range that is slightly higher (more basic) than many of the other executioner caspases. This broad range indicates that caspase-3 will be fully active under normal and apoptotic cell conditions.

Regulation

Activation

Caspase-3 is activated in the apoptotic cell both by extrinsic (death ligand) and intrinsic (mitochondrial) pathways. The zymogen feature of caspase-3 is necessary because if unregulated, caspase activity would kill cells indiscriminately. As an executioner caspase, the caspase-3 zymogen has virtually no activity until it is cleaved by an initiator caspase after apoptotic signaling events have occurred. One such signaling event is the introduction of granzyme B, which can activate initiator caspases, into cells targeted for apoptosis by killer T cells. This extrinsic activation then triggers the hallmark caspase cascade characteristic of the apoptotic pathway, in which caspase-3 plays a dominant role. In intrinsic activation, cytochrome c from the mitochondria works in combination with caspase-9, apoptosis-activating factor 1 (Apaf-1), and ATP to process procaspase-3. These molecules are sufficient to activate caspase-3 in vitro, but other regulatory proteins are necessary in vivo. Mangosteen (Garcinia mangostana) extract has been shown to inhibit the activation of caspase 3 in B-amyloid treated human neuronal cells.

Inhibition

One means of caspase inhibition is through the IAP (inhibitor of apoptosis) protein family, which includes c-IAP1, c-IAP2, XIAP, and ML-IAP. XIAP binds and inhibits initiator caspase-9, which is directly involved in the activation of executioner caspase-3. During the caspase cascade, however, caspase-3 functions to inhibit XIAP activity by cleaving caspase-9 at a specific site, preventing XIAP from being able to bind to inhibit caspase-9 activity.

Interactions

Caspase 3 has been shown to interact with:

• CASP8
• NMT2
• CFLAR
• DCC
• GroEL
• HCLS1
• Survivin
• TRAF3
• XIAP
• NFE2L2

References

References

1. "OrthoMaM phylogenetic marker: CASP3 coding sequence".
2. (October 1996). "Human ICE/CED-3 protease nomenclature". Cell.
3. (April 1999). "Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation". Cell.
4. "Entrez Gene: CASP3 caspase 3, apoptosis-related cysteine peptidase".
5. (1997). "Apoptosis: an overview". British Medical Bulletin.
6. (July 1997). "Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis". The Journal of Biological Chemistry.
7. (September 2000). "Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8". The Biochemical Journal.
8. (January 2002). "Caspases: opening the boxes and interpreting the arrows". Cell Death and Differentiation.
9. (December 1994). "CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme". The Journal of Biological Chemistry.
10. (June 1995). "Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase". Cell.
11. (July 1995). "Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis". Nature.
12. (October 2005). "Caspases: pharmacological manipulation of cell death". The Journal of Clinical Investigation.
13. (2019). "The prodomain of caspase-3 regulates its own removal and caspase activation". Cell Death Discovery.
14. (2022). "Caspase 3 and its role in the pathogenesis of cancer.". Clin. Oncol..
15. (January 2011). "Serum caspase-3 p17 fragment is elevated in patients with ST-segment elevation myocardial infarction: a novel observation". Journal of the American College of Cardiology.
16. (June 2008). "Rehabilitation of a contract killer: caspase-3 directs stem cell differentiation". Cell Stem Cell.
17. (September 2007). "Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis". The FEBS Journal.
18. (July 2006). "Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition". Journal of Molecular Biology.
19. (October 2008). "Caspases: structure-guided design of drugs to control cell death". Mini Reviews in Medicinal Chemistry.
20. (February 1999). "Emerging roles of caspase-3 in apoptosis". Cell Death and Differentiation.
21. (October 1997). "Biochemical characteristics of caspases-3, -6, -7, and -8". The Journal of Biological Chemistry.
22. (Dec 2008). "Construction and analysis of a modular model of caspase activation in apoptosis". Theoretical Biology & Medical Modelling.
23. (August 2009). "Apoptosis and cancer: mutations within caspase genes". Journal of Medical Genetics.
24. (December 2003). "Mechanisms of caspase activation". Current Opinion in Cell Biology.
25. (December 2009). "A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis". The Biochemical Journal.
26. (September 2001). "Apoptosis: live or die--hard work either way!". Hormone and Metabolic Research.
27. (2001). "Novel procaspase-3 activating cascade mediated by lysoapoptases and its biological significances in apoptosis". Advances in Enzyme Regulation.
28. (January 2004). "Mitochondrial activation of apoptosis". Cell.
29. (May 2010). "Protective effect of mangosteen extract against beta-amyloid-induced cytotoxicity, oxidative stress and altered proteome in SK-N-SH cells". Journal of Proteome Research.
30. (July 2007). "Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9". The Biochemical Journal.
31. (April 2002). "Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria". The Journal of Biological Chemistry.
32. (December 1996). "Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases". Proceedings of the National Academy of Sciences of the United States of America.
33. (May 2007). "Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer (Review)". International Journal of Molecular Medicine.
34. (June 1997). "Casper is a FADD- and caspase-related inducer of apoptosis". Immunity.
35. (October 1997). "MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death". Proceedings of the National Academy of Sciences of the United States of America.
36. (March 2001). "The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation". Proceedings of the National Academy of Sciences of the United States of America.
37. (April 1999). "Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells". The EMBO Journal.
38. (April 1999). "Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis". The EMBO Journal.
39. (May 2002). "Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells". The Biochemical Journal.
40. (November 2001). "Caspase-mediated cleavage of actin-binding and SH3-domain-containing proteins cortactin, HS1, and HIP-55 during apoptosis". Biochemical and Biophysical Research Communications.
41. (December 1998). "IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs". Cancer Research.
42. (January 2001). "An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7". Biochemistry.
43. (March 2001). "Caspase-mediated cleavage of TRAF3 in FasL-stimulated Jurkat-T cells". Journal of Leukocyte Biology.
44. (March 2001). "TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis". The Journal of Biological Chemistry.
45. (July 2001). "Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death". Proceedings of the National Academy of Sciences of the United States of America.
46. (April 2002). "The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites". The Journal of Cell Biology.
47. (March 2001). "Structural basis for the inhibition of caspase-3 by XIAP". Cell.
48. (December 1997). "The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases". The EMBO Journal.
49. (July 1997). "X-linked IAP is a direct inhibitor of cell-death proteases". Nature.
50. (July 2001). "X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes". The Journal of Biological Chemistry.
51. (September 1999). "Identification of NRF2, a member of the NF-E2 family of transcription factors, as a substrate for caspase-3(-like) proteases". Cell Death and Differentiation.